๐Ÿ“ˆ Modern Diagnostic & Research Centre Ltd IPO โ€“ All You Need to Know! ๐Ÿš€

page-banner-circle
blog-page-banner
Spread the love

The Modern Diagnostic & Research Centre Ltd IPO is creating buzz in the market as one of the key SME IPOs closing out the year! If youโ€™re planning to invest or simply want the latest update, hereโ€™s everything you need to know โ€” clearly explained and enhanced with emojis for better engagement ๐Ÿ˜Š.


๐Ÿ—“๏ธ IPO Timeline

๐Ÿ“… IPO Open Date: 31 December 2025
๐Ÿ“… IPO Close Date: 2 January 2026
๐Ÿ“… Basis of Allotment: 5โ€“6 January 2026
๐Ÿ“… Expected Listing Date: 7 January 2026
๐Ÿ“ Exchange: BSE SME

This is one of the final IPOs of 2025, attracting strong attention due to the year-end lull in new issues ๐Ÿ“Š.


๐Ÿ’ฐ IPO Price Band & Issue Size

๐Ÿ’ธ Price Band: โ‚น85 โ€“ โ‚น90 per share
๐Ÿ“Š Total Issue Size: Approx โ‚น36.89 Crore (Fresh Issue Only)
๐Ÿ“ฆ Face Value: โ‚น10 per share
๐Ÿ“ˆ Total Shares Offered: 40,99,200 equity shares

This IPO follows the Book Building route, with bids accepted within the price band.


๐Ÿ“ฆ Lot Size & Investment Details

๐Ÿ”น Lot Size: 1,600 equity shares
๐Ÿ”น Minimum Retail Investment: โ‚น144,000
๐Ÿ”น Maximum Retail Investment: โ‚น288,000 (2 lots)

Suitable for investors comfortable with higher-ticket SME IPO investments.


๐Ÿ‘ฅ Category-wise Allocation

โœ”๏ธ Anchor / QIB: Up to 11,61,600 shares
โœ”๏ธ QIB (Non-anchor): Up to 7,82,400 shares
โœ”๏ธ NII / HNI: Minimum 5,85,600 shares
โœ”๏ธ Retail Investors: Minimum 13,63,200 shares
โœ”๏ธ Market Maker Portion: 2,06,400 shares


๐Ÿงช About Modern Diagnostic & Research Centre Ltd (MDRC)

Modern Diagnostic & Research Centre Ltd is a well-established diagnostic services provider, offering a wide spectrum of medical tests and imaging services. Its offerings include:

โœ” Advanced Pathology Tests
โœ” Radiology & Imaging (CT, MRI, Ultrasound, X-ray)
โœ” Wellness Packages
โœ” Home Sample Collection
โœ” Corporate & Hospital Diagnostic Partnerships
โœ” Digital Reports & Patient Support

The company operates 21 diagnostic facilities, including 17 labs and 4 collection/centres, across multiple states โ€” positioning itself strongly in Indiaโ€™s expanding diagnostic healthcare ecosystem.


๐ŸŒŸ Why Investors Are Watching This IPO

โœจ Healthcare Sector Growth: Demand for diagnostics continues to rise post-COVID, boosting opportunities for expansion.
โœจ Infrastructure Expansion: Funds will be used to purchase advanced medical equipment & strengthen their lab network.
โœจ Working Capital Support: Improving financial flexibility for growth.
โœจ Year-end SME Highlight: Fewer IPOs at this time means more focus & participation.


๐Ÿ” Key Points for Investors

๐Ÿ‘‰ SME IPOs carry higher risk, but may also offer higher growth potential.
๐Ÿ‘‰ Minimum investment is significantly higher than regular mainboard IPOs.
๐Ÿ‘‰ Study subscription numbers, financial performance & GMP trends before applying.
๐Ÿ‘‰ Ensure alignment with your financial goals and risk appetite.


๐Ÿ’ก Final Thoughts

The Modern Diagnostic & Research Centre Ltd IPO stands out as a notable SME offering closing out 2025. With strong presence in diagnostics, expansion plans, and market interest, it may appeal to investors looking for opportunities in the healthcare sector ๐Ÿ”ฌ๐Ÿ“Š.

However, as always, due diligence and risk assessment are essential before subscribing to any IPO.


โš ๏ธ Disclaimer

The investments & trading ideas recommended in the market analysis, research reports, etc. may not be suitable for all investors. This article or data points do not constitute investment advice, as stock market investments are subject to market risks. Please consult your financial advisor before making any investment or trading decisions.

All information provided is a point of view and is strictly for educational, learning, and informational purposes only. The author or group admin accepts no liability for any interpretation of the articles or comments on this platform being used for actual investments.

Registration granted by SEBI and certification from NISM in no way guarantee performance of any intermediary or provide assurance of returns. Investors must make their own decisions based on their specific financial goals, risk appetite and personal financial situation after consulting with a registered market professional.